Who is sponsoring NCT06812039?

NCT06812039 is sponsored by Fudan University.

What drugs are being tested in NCT06812039?

Interventions in NCT06812039: HAIC combined with sintilimab and donafenib, Sintilimab and Donafenib, Surgery.

What condition does NCT06812039 study?

NCT06812039 studies Hepato Cellular Carcinoma (HCC).

Is NCT06812039 still recruiting?

NCT06812039 is currently recruiting now. Last updated 6 February 2025.

Last reviewed 2025-02-06 · How we verify

NCT06812039

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence

Recruiting now Phase 2 Last updated 6 February 2025

What this trial tests

Phase 2 trial testing HAIC combined with sintilimab and donafenib in Hepato Cellular Carcinoma (HCC) in 165 participants. Currently enrolling.

Timeline

1 January 2025

Primary endpoint
31 December 2026

31 January 2028

Quick facts

Lead sponsor	Fudan University
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	165
Start date	1 January 2025
Primary completion	31 December 2026
Estimated completion	31 January 2028
Sites	3 locations across China

Drugs / interventions tested

HAIC combined with sintilimab and donafenib — full drug profile →
Sintilimab and Donafenib — full drug profile →
Surgery

Conditions studied

Hepato Cellular Carcinoma (HCC) — all drugs for Hepato Cellular Carcinoma (HCC) →

Sponsor

Fudan University

Who can join

Adults 18 to 75, any sex, with Hepato Cellular Carcinoma (HCC). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate the efficacy and safety of therapy perioperative treatment with HAIC combined with donafenib and sintilimab (group A)/ donafenib combined with sintilimab (group B) compared with direct surgery (group C) in resectable HCC patients who are at high risk for disease recurrence.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hepato Cellular Carcinoma (HCC)

Currently open trials in the same condition.

NCT07276100 — Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With Atezoli · Phase 2 · recruiting
NCT06990659 — Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC) · NA · recruiting
NCT06960863 — Fibroscan Evaluating Immunotherapy Response in Hepatocellular Carcinoma · recruiting
NCT06960954 — PIVKA-II for Predicting Portal Vein Thrombosis in Hepatocellular Carcinoma · recruiting
NCT06742424 — PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC · Phase 2 · recruiting

Other Fudan University trials

Trials by the same sponsor.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06812039 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fudan University
Last refreshed: 6 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06812039.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing